Label mix-up sparks Qualitest recall; India lowers boom on counterfeiters;

> Qualitest is recalling lots of phenobarbital tablets and lots of hydrocodone bitartrate and acetaminophen tablets after a bottle of the latter was labeled as the former. Recall notice

> India is cracking down on counterfeiters: special courts are being set up to try such cases quickly; the maximum sentence is extended to life; fines are raised to three times the value of the drugs confiscated; compensation will be made to those affected. Article

> Eighteen people now face prosecution in China as a result of the injuries from fake Avastin. Article

> And Indian regulators area apparently again changing their minds about an aging vaccine lab in Chennai, shut down for GMP noncompliance in 2008 and then ordered remediated and reopened in 2010--it may now become a drug testing lab. Story

> CMO Dalton Pharma will provide API manufacturing and aseptic fill/finish services to specialty pharma Oncovir, a developer of nucleic-acid-based therapies. Dalton release

> Lotus Pharmaceuticals is adding two additional stories to its new headquarters building in Beijing. Lotus release

> ALDA Pharmaceuticals plans to equip itself to manufacture infection-control therapeutics by buying the assets of Seavan Health & Beauty. Story

> Intellipharmaceutics International has hired Doll Consulting for help commercializing its controlled-release generic drug portfolio. Intellipharmaceutics release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.